Gottlieb Leaves FDA With Final Thought On What To Do About Cosmetics
Executive Summary
Addressing for the last time the House Appropriations subcommittee with FDA oversight, Commissioner Scott Gottlieb shared his vision for sharpening cosmetics oversight in the absence of significant new resources.
You may also be interested in...
ICMAD: Federal Cosmetics Legislation Without National Uniformity Not In Industry’s Interest
If the goal of bills like the proposed Personal Care Products Safety Act is to shore up consumers’ trust in the safety of cosmetic products, national uniformity is an indispensable component, says eos Products President Sanjiv Mehra, chairman of ICMAD’s board.
Gottlieb's Parting Words For US FDA: 'Be Willing To Push' For Major Policy Changes
Outgoing Commissioner tells staff, “No phrase bothered me more than when I heard people say to me they didn’t want to do something important because they wanted to ‘preserve their political capital.’” FDA should not to worry about spending political capital, Gottlieb argued, because it is replenished upon accomplishing important things.
Gottlieb Unleashed: Focus on Drug Pricing To Intensify As He Rejoins AEI
Without constraints of being FDA commissioner, Gottlieb will have podium to push for changes to drug pricing and competition.